Bill Wexler's Profits of DOOM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Wexler who wrote (4107)	1/1/1999 5:15:00 PM
From: Bill Wexler	Read Replies (5) of 4634

Details of one of the many class action complaints against Zonagen... securities.stanford.edu Of particular interest are paragraphs 34 and 49: 34. Nevertheless, in 1996, Zonagen moved forward with phase III trials for Vasomax, one in Mexico and two in the U.S. The Company also announced in June 1996 that the U.S. Patent Office had approved its patent covering the melt in the mouth use of Vasomax as a treatment of erectile dysfunction. Zonagen, however, failed to disclose that the patent office had rejected the Company's more specific application for a patent to cover the use of phentolamine as a pill to be swallowed for the treatment of impotence. According to Fortune magazine's March 16, 1998 article, defendant Podolski conceded in a recent interview that "[y]ou can say today no patent specifically covers Vasomax." (Emphasis added) 49. The Fortune article raised potentially severe safety concerns regarding the swallowing of phentolamine as a treatment for impotence, How safe is it? Vasomax raises a burning issue. . . How can a drug delivered via the bloodstream dilate penile arteries without similarly affecting blood vessels throughout the body, risking severe side effects? After all, even localized injections of 'vasodilating drugs in the penis occasionally cause sudden bodywide drops in blood pressure, accompanied by dizziness and fainting... From the beginning Zonagen and its consultants -- along with the FDA -- had been concerned about the drug's safety... [and] safety concerns can slow a drug's approval and lead to label warnings that could potentially limit its use...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next